康拓医疗
(688314)
| 流通市值：25.11亿 | | | 总市值：25.11亿 |
| 流通股本：8162.83万 | | | 总股本：8162.83万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 170,964,676.44 | 73,682,439.89 | 351,075,997.28 | 251,088,755.11 |
| 营业收入 | 170,964,676.44 | 73,682,439.89 | 351,075,997.28 | 251,088,755.11 |
| 二、营业总成本 | 124,990,550.06 | 58,475,258.37 | 227,251,252.35 | 156,565,067.29 |
| 营业成本 | 38,729,676.01 | 17,150,217.27 | 74,820,595.97 | 53,498,332.85 |
| 税金及附加 | 2,720,016.16 | 1,053,998.92 | 5,312,725.36 | 4,010,665.78 |
| 销售费用 | 30,084,267.3 | 13,700,493.51 | 64,684,972.47 | 44,244,814.17 |
| 管理费用 | 34,410,773.41 | 17,708,906.19 | 56,508,904.3 | 37,100,985.95 |
| 研发费用 | 18,563,315.23 | 8,303,286.73 | 25,644,883.33 | 17,980,206.24 |
| 财务费用 | 482,501.95 | 558,355.75 | 279,170.92 | -269,937.7 |
| 其中:利息费用 | 1,487,661.17 | 573,735.3 | 2,321,892.79 | 1,688,766.26 |
| 其中:利息收入 | 1,624,633.7 | 275,218.93 | 2,029,701.79 | 1,775,191.05 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 279,167.5 | -324,972.23 | -285,272.93 | -1,076,419.63 |
| 加:投资收益 | -25,536.01 | -645,544.82 | -8,923,062.6 | -8,632,975.85 |
| 资产处置收益 | 0 | 0 | 713.5 | 0 |
| 资产减值损失(新) | -1,503,894.09 | -993,624.05 | -4,156,542.61 | -564,926.19 |
| 信用减值损失(新) | -1,261,155.72 | 454,829.69 | -1,185,977.97 | -291,024.28 |
| 其他收益 | 2,974,648.65 | 494,649.97 | 1,475,190.97 | 1,008,230.63 |
| 四、营业利润 | 46,437,356.71 | 14,192,520.08 | 110,749,793.29 | 84,966,572.5 |
| 加:营业外收入 | 2,428,443.11 | 129,004.75 | 5,286,551.1 | 4,788,230.89 |
| 减:营业外支出 | 2,172,987.09 | 15,085.99 | 516,805.55 | 30,401.99 |
| 五、利润总额 | 46,692,812.73 | 14,306,438.84 | 115,519,538.84 | 89,724,401.4 |
| 减:所得税费用 | 6,289,112.04 | 1,640,135.8 | 17,771,222.01 | 13,818,265.97 |
| 六、净利润 | 40,403,700.69 | 12,666,303.04 | 97,748,316.83 | 75,906,135.43 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 40,403,700.69 | 12,666,303.04 | 97,748,316.83 | 75,906,135.43 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 41,393,683.21 | 13,158,946.7 | 98,703,534.38 | 76,715,151.84 |
| 少数股东损益 | -989,982.52 | -492,643.66 | -955,217.55 | -809,016.41 |
| 扣除非经常损益后的净利润 | 37,694,138.73 | 12,929,580.88 | 91,741,398.31 | 71,607,544.11 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.51 | 0.16 | 1.21 | 0.94 |
| (二)稀释每股收益 | 0.51 | 0.16 | 1.21 | 0.94 |
| 八、其他综合收益 | -378,935.79 | -286,265.89 | 3,482,497.86 | -753,129.35 |
| 归属于母公司股东的其他综合收益 | -409,523.64 | -300,828.42 | 3,460,007.37 | -766,066.89 |
| 九、综合收益总额 | 40,024,764.9 | 12,380,037.15 | 101,230,814.69 | 75,153,006.08 |
| 归属于母公司股东的综合收益总额 | 40,984,159.57 | 12,858,118.28 | 102,163,541.75 | 75,949,084.95 |
| 归属于少数股东的综合收益总额 | -959,394.67 | -478,081.13 | -932,727.06 | -796,078.87 |
| 公告日期 | 2026-08-28 | 2026-04-29 | 2026-03-31 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |